Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Down – What’s Next?

Posted by Brian Himes on Sep 14th, 2026

Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report)’s share price gapped down prior to trading on Monday . The stock had previously closed at $20.59, but opened at $18.55. Cullinan Therapeutics shares last traded at $20.00, with a volume of 230,917 shares traded.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on CGEM shares. TD Cowen raised Cullinan Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. BTIG Research upped their target price on Cullinan Therapeutics from $38.00 to $39.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cullinan Therapeutics in a report on Wednesday, July 8th. Wall Street Zen downgraded Cullinan Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday. Finally, Wedbush boosted their price objective on Cullinan Therapeutics from $39.00 to $42.00 and gave the stock an “outperform” rating in a report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $32.86.

Check Out Our Latest Analysis on Cullinan Therapeutics

Cullinan Therapeutics Trading Down 2.4%

The stock has a 50 day simple moving average of $19.46 and a 200 day simple moving average of $16.43. The firm has a market capitalization of $1.29 billion, a PE ratio of -6.44 and a beta of 0.02.

Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.01). As a group, equities analysts anticipate that Cullinan Therapeutics, Inc. will post -3.08 earnings per share for the current year.

Insider Buying and Selling

In other Cullinan Therapeutics news, insider Jennifer Michaelson sold 8,000 shares of the stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $21.57, for a total transaction of $172,560.00. Following the completion of the sale, the insider owned 158,844 shares of the company’s stock, valued at $3,426,265.08. This represents a 4.79% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In the last three months, insiders have sold 46,000 shares of company stock worth $922,920. Corporate insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On Cullinan Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Integrated Wealth Concepts LLC purchased a new stake in shares of Cullinan Therapeutics during the second quarter worth about $25,000. Caitong International Asset Management Co. Ltd grew its stake in shares of Cullinan Therapeutics by 62.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,696 shares of the company’s stock worth $28,000 after purchasing an additional 1,036 shares during the last quarter. Allworth Financial LP purchased a new position in Cullinan Therapeutics during the 2nd quarter valued at about $53,000. Quantbot Technologies LP purchased a new position in Cullinan Therapeutics during the 2nd quarter valued at about $53,000. Finally, Seven Fleet Capital Management LP bought a new position in Cullinan Therapeutics during the 4th quarter valued at approximately $31,000. 86.31% of the stock is owned by institutional investors.

About Cullinan Therapeutics

(Get Free Report)

Cullinan Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer and other serious diseases. The company’s approach combines internally developed drug candidates with licensed or acquired programs and partnerships intended to address areas of significant unmet medical need.

Its pipeline has included zipalertinib, an oral tyrosine kinase inhibitor being developed for patients with non-small cell lung cancer whose tumors have EGFR exon 20 insertion mutations.